A Phase II Study of BAY 1000394 in MCL1-Amplified, MYC-Amplified, CCNE1-Amplified Tumors

Trial Profile

A Phase II Study of BAY 1000394 in MCL1-Amplified, MYC-Amplified, CCNE1-Amplified Tumors

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs Roniciclib (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jun 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as development of BAY1000394 has been terminated by Bayer.
    • 28 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top